Novo Nordisk's Wegovy clinical data beats Eli Lilly, leading the European stock medical sector

According to Zhitong Finance APP, on Monday, European stock markets rose slightly, with the healthcare sector being a major support force. Earlier data showed that Denmark's pharmaceutical giant Novo Nordisk (NVO.US) had better heart protection effects with its weight loss drug Wegovy compared to the similar product from Eli Lilly (LLY.US), leading to an increase in its stock price.

As of the time of writing, the pan-European Stoxx 600 index was up 0.29%, at 551.72 points. Last Friday, the index had just experienced its first weekly decline in four weeks.

Among them, the healthcare sector was one of the best-performing industry sectors of the day. As the fourth largest healthcare company in the Stoxx index, Novo Nordisk's stock price rose nearly 3%. Earlier, the company's real-world comparative data showed that Wegovy (semaglutide) could reduce the risk of heart attack, stroke, or death by 57% compared to Eli Lilly's competing drugs Mounjaro (tirzepatide) and Zepbound (tirzepatide injection).

The defense sector in the European market also performed well, with an increase of 1.2%. Among them, the stock price of BAE Systems rose by 2%, and Norway has announced that it has chosen the UK as its strategic partner for procuring new frigates, with this deal valued at approximately £10 billion (equivalent to $13.51 billion).

Last Friday, the U.S. Court of Appeals ruled that most of the tariffs imposed by President Donald Trump were illegal, but allowed these tariffs to remain in effect until mid-October to allow time for subsequent appeals. It is worth noting that due to the U.S. holiday on that day, the market trading volume is expected to remain at a low level throughout the day